Bluebird Bio Inc (BLUE) 94.30 $BLUE
Jim Cramer -- Microsoft, General Mills, WhiteWave Are Buying Opportunities
at The Street - Wed Oct 07, 11:59AM CDT
Jim Cramer answers viewers questions from social media on the floor of the New York Stock Exchange.
BLUE: 94.30 (-0.50), BIIB: 279.24 (+3.25), FB: 92.40 (-0.40), XOM: 79.20 (+1.31), AMGN: 148.05 (+6.83), LLY: 83.99 (-0.18), BMY: 60.55 (+0.67), INTC: 32.31 (+0.57), CELG: 116.98 (+4.79), WWAV: 41.76 (-0.20), MSFT: 46.80 (+0.05), TWTR: 29.83 (+2.21), CVX: 88.12 (+1.13), GIS: 55.72 (+0.02)
3 Biotech Stocks That Have Been Unfairly Beaten Down
Brian Feroldi, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Tue Oct 06, 7:43AM CDT
Image by Gerald/Pixabay. What a brutal past few days it's been for biotech stocks. A simple tweet last week from presidential hopeful Hillary Clinton has caused biotech investors to get in a tizzy, and they've been selling off biotechs of all...
BLUE: 94.30 (-0.50), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56)
Analysts' Actions -- Twitter, AutoZone, Tyco, Viacom
at The Street - Mon Oct 05, 7:43AM CDT
Here are Monday's top research calls, including ratings changes at Twitter, AutoZone, Tyco and Viacom.
BLUE: 94.30 (-0.50), TYC: 35.58 (+0.41), NSC: 81.20 (+1.77), FEYE: 32.12 (+0.94), NUE: 40.58 (+0.66), FCX: 13.01 (+1.18), OUT: 23.14 (-0.03), SNI: 54.62 (+2.96), DIN: 89.94 (-0.45), TWX: 71.80 (+0.39), BUFF: 17.50 (+0.39), AZO: 736.00 (-8.62), LRCX: 66.56 (+1.31), AMAT: 15.39 (+0.15), TWTR: 29.83 (+2.21), VIAB: 47.45 (+0.66), ROK: 103.12 (-1.21), UNP: 95.11 (+1.72)
5 Stocks Poised for Breakouts
at The Street - Fri Oct 02, 8:16AM CDT
These stocks look ready to break out and trade higher from current levels.
BLUE: 94.30 (-0.50), W: 38.26 (-1.09), OVAS: 11.28 (+0.45), OFG: 9.41 (+0.19), ALB: 48.91 (+1.30)
BUYINS.NET: BLUE SqueezeTrigger Price is $88.75. There is $267,163,208 That Short Sellers Still Need To Cover.
M2 - Tue Sep 29, 10:07AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Blue Martini Software Inc (NASDAQ:BLUE) in real time and just received an alert that BLUE is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 2969800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $88.75. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BLUE: 94.30 (-0.50)
Weakness Seen in bluebird (BLUE): Stock Tumbles 13.3%
Zacks Equity Research - Zacks Investment Research - Tue Sep 29, 7:38AM CDT
bluebird saw a big move last session as the company's shares fell by over 13% on the day
BLUE: 94.30 (-0.50), ANIK: 32.27 (+0.60)
Alexandria Real Estate Equities, Inc. Announces 10-Year 253,000 RSF Full-Building Build-to-Suit Lease at 60 Binney Street for bluebird bio for Its New Office/Laboratory Headquarters in the Heart of Kendall Square in Cambridge, MA
PR Newswire - Tue Sep 29, 7:30AM CDT
Alexandria Real Estate Equities, Inc. (NYSE: ARE), the largest and leading office REIT uniquely focused on collaborative science and technology campuses in urban innovation clusters, is pleased to announce that bluebird bio, Inc. (Nasdaq: BLUE) executed a 10-year lease for approximately 253,000 rentable square feet (RSF) at 60 Binney Street at the Alexandria Center® at Kendall Square campus. The lease encompasses the entire 60 Binney Street building with the exception of a ground-floor retail suite. With the relocation of its headquarters to 60 Binney Street, bluebird bio, a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, will be expanding its presence in Cambridge to support the company's continued growth. The 60 Binney Street project, which is targeting LEED Gold Certification, is expected to be delivered in late 2016.
BLUE: 94.30 (-0.50), ARE: 88.38 (+0.75)
Global Gene Therapy Market Outlook 2020
M2 - Tue Sep 29, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xn4mxb/global_gene) has announced the addition of the "Global Gene Therapy Market Outlook 2020" report to their offering. According to this new research report Global Gene Therapy Market Outlook 2020, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the gene therapy market, such as phases, geographies, vector types, etc. As indicated by the new estimation carried out in our most recent study, the global gene therapy industry can possibly turn into a multi-million dollar industry by the end of 2020, as new products, particularly those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. The gene therapy market has very few marketed products. The market is majorly in the research phase from which most of its revenue is generated. The report also provides the sales of major marketed gene therapy products and the list of the products in clinical/pre-clinical research along with their clinical phases. The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms, which are aiding them to develop new products. The study highlights the applications for which the investments have been received. Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. The report provides the market analysis of key therapeutic areas along with the forecast till 2020. North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction 4. Industry Overview 5. Clinical Trial Assessment & Pipeline Analysis 6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario 7. Marketed Gene Therapies 8. Global Gene Therapy Market 9. Gene Therapy Market by Application 10. Global Gene Therapy Market Size by Geography 11. Competitive Landscape 12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses) - Advantagene Inc. - Bluebird Bio - Genethon - Human Stem Cells Institute - Oxford BioMedica Plc - Sanofi - Shanghai Sunway Biotech Co. Ltd. - Sibiono GeneTech Co. Ltd. - Spark Therapeutics, LLC - UniQure N.V. - Vical Inc. - ViroMed Co. Ltd. dba VM BioPharma For more information visit http://www.researchandmarkets.com/research/xn...lobal_gene
BLUE: 94.30 (-0.50), VICL: 0.45 (-0.01), ONCE: 44.81 (-5.59)
5 Sell-Ranked Biotechs That Fell More Than 5% Today
A Clark - Zacks Investment Research - Fri Sep 25, 4:53PM CDT
The biotech sector has been struggling as of late, and Friday was an especially tough day for many biotech stocks. Read on for 5 stocks that suffered losses of at least 5% on the day.
BLUE: 94.30 (-0.50), OREX: 2.26 (+0.06), ALDR: 31.14 (-1.43), ACAD: 32.78 (+0.42), ANIP: 45.33 (+1.78)
Why bluebird bio Inc Shares Slumped Again
Brian Feroldi, The Motley Fool - Motley Fool - Fri Sep 25, 2:42PM CDT
What: Shares of bluebird bio , a clinical-stage biotechnology company with a focus on gene therapy, flew south today on heavy trading volume -- its stock was down more than 11% in afternoon trading. So what: For the second time this week...
BLUE: 94.30 (-0.50)
Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet, Global Blood Weighs on Bluebird
at The Street - Fri Sep 25, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 94.30 (-0.50), GBT: 49.11 (+1.07), BMRN: 102.13 (-1.11), GILD: 100.27 (+2.73), ONCE: 44.81 (-5.59), SRPT: 37.97 (-0.03), PTCT: 31.49 (+2.44), IBB: 307.79 (+5.88)
bluebird bio Announces Participation in Leerink Partners Immuno-Oncology Roundtable
Business Wire - Thu Sep 24, 3:05PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in the Leerink Partners Immuno-Oncology Roundtable on Thursday, October 1, 2015, with a fireside chat at 1:30 p.m. ET. The conference is being held at Le Parker Meridien Hotel in New York City.
BLUE: 94.30 (-0.50)
Market Pulse of Healthcare Sector - Concert Pharmaceuticals, Clovis Oncology, bluebird bio, ACADIA Pharmaceuticals and DENTSPLY International
PR Newswire - Thu Sep 24, 7:39AM CDT
ACI Association has initiated research coverage on the following equities: Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), Clovis Oncology, Inc. (NASDAQ: CLVS), bluebird bio, Inc. (NASDAQ: BLUE), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), DENTSPLY International Inc. (NASDAQ: XRAY). On Wednesday, September 23, 2015, NASDAQ ended at 4,752.74 down 0.08%, Dow Jones declined 0.31%, to finish the day at 16,279.89, and the S&P closed at 1,938.76, down 0.20%. Register for your complimentary reports at the links given below.
BLUE: 94.30 (-0.50), ACAD: 32.78 (+0.42), CLVS: 91.75 (+1.36), XRAY: 54.48 (+1.78), CNCE: 20.11 (+1.00)
Did Hillary Clinton Cause bluebird bio to Slump Today?
Brian Feroldi, The Motley Fool - Motley Fool - Mon Sep 21, 1:21PM CDT
What's happening: Shares of bluebird bio , a clinical-stage biotechnology company with a focus on gene therapy, were shot down today on higher than normal volume, falling by more than 12% at one point today before slightly rebounding to a loss of...
BLUE: 94.30 (-0.50)
IPO Stock Watch: Regenxbio Jumps On First Trading Day
at Investor's Business Daily - Thu Sep 17, 3:20PM CDT
Regenxbio (RGNX) popped on the first trading day of its upsized initial public offering, which raised $138.6 million for the drugmaker. Regenxbio priced at 22 and opened at 30.26, up 38%, and remained near there in midday trading. It had previously...
BLUE: 94.30 (-0.50), RGNX: 23.40 (+1.20), ONCE: 44.81 (-5.59), PEN: 41.11 (+1.77), NBRV: 10.27 (unch)
Regenxbio Turns In Strong, Upsized IPO Performance
at Investor's Business Daily - Wed Sep 16, 5:22PM CDT
Regenxbio (RGNX) turned in a strong performance Wednesday, with an upsized initial public offering that raised $138.6 million. The biotech company priced 6.3 million shares, above previous plans to offer 5.6 million shares, at 22 a share. Its initial...
BLUE: 94.30 (-0.50), RGNX: 23.40 (+1.20), ONCE: 44.81 (-5.59), PEN: 41.11 (+1.77), NBRV: 10.27 (unch)
Investor Interest Looks Strong For Regenxbio IPO
at Investor's Business Daily - Wed Sep 16, 4:45PM CDT
Demand for Regenxbio (RGNX) stock is strong heading into the pricing of its initial public offering, scheduled to occur late Wednesday. Research firm IPOboutique.com says channel checks reveal, according to underwriter guidance, that the deal is now...
BLUE: 94.30 (-0.50), ONCE: 44.81 (-5.59)
MPM Capital appoints Mitchell H. Finer PhD, former bluebird bio CSO, as Managing Director.
Business Wire - Tue Sep 15, 1:15PM CDT
MPM Capital announces the appointment of Mitchell H. Finer PhD (Mitch) as Managing Director (MD). Mitch also serves on the Board of Directors of MPM's portfolio company Semma Therapeutics, Inc.
BLUE: 94.30 (-0.50)
Will Kite (KITE) Get Orphan Status Again in EU for KTE-C19?
Arpita Dutt - Zacks Investment Research - Mon Sep 14, 1:56PM CDT
The COMP has adopted a positive opinion regarding the granting of orphan drug status to Kite's (KITE) KTE-C19 for the treatment of PMBCL and MCL.
BLUE: 94.30 (-0.50), GILD: 100.27 (+2.73), KITE: 64.57 (+1.60), AMGN: 148.05 (+6.83)
3 Clinical Trials to Watch As Bluebird Bio Rounds Out 2015
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 14, 1:07AM CDT
bluebird bio is well off its summer highs, but the gene therapy company is still having a solid year, up 44% since January. BLUE data by YCharts The downturn appears to have little to do with what bluebird bio has done -- or not done...
BLUE: 94.30 (-0.50)
Jim Cramer -- Microsoft, General Mills, WhiteWave Are Buying Opportunities
at The Street - Wed Oct 07, 11:59AM CDT
Jim Cramer answers viewers questions from social media on the floor of the New York Stock Exchange.
BLUE: 94.30 (-0.50), BIIB: 279.24 (+3.25), FB: 92.40 (-0.40), XOM: 79.20 (+1.31), AMGN: 148.05 (+6.83), LLY: 83.99 (-0.18), BMY: 60.55 (+0.67), INTC: 32.31 (+0.57), CELG: 116.98 (+4.79), WWAV: 41.76 (-0.20), MSFT: 46.80 (+0.05), TWTR: 29.83 (+2.21), CVX: 88.12 (+1.13), GIS: 55.72 (+0.02)
3 Biotech Stocks That Have Been Unfairly Beaten Down
Brian Feroldi, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Tue Oct 06, 7:43AM CDT
Image by Gerald/Pixabay. What a brutal past few days it's been for biotech stocks. A simple tweet last week from presidential hopeful Hillary Clinton has caused biotech investors to get in a tizzy, and they've been selling off biotechs of all...
BLUE: 94.30 (-0.50), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56)
Analysts' Actions -- Twitter, AutoZone, Tyco, Viacom
at The Street - Mon Oct 05, 7:43AM CDT
Here are Monday's top research calls, including ratings changes at Twitter, AutoZone, Tyco and Viacom.
BLUE: 94.30 (-0.50), TYC: 35.58 (+0.41), NSC: 81.20 (+1.77), FEYE: 32.12 (+0.94), NUE: 40.58 (+0.66), FCX: 13.01 (+1.18), OUT: 23.14 (-0.03), SNI: 54.62 (+2.96), DIN: 89.94 (-0.45), TWX: 71.80 (+0.39), BUFF: 17.50 (+0.39), AZO: 736.00 (-8.62), LRCX: 66.56 (+1.31), AMAT: 15.39 (+0.15), TWTR: 29.83 (+2.21), VIAB: 47.45 (+0.66), ROK: 103.12 (-1.21), UNP: 95.11 (+1.72)
5 Stocks Poised for Breakouts
at The Street - Fri Oct 02, 8:16AM CDT
These stocks look ready to break out and trade higher from current levels.
BLUE: 94.30 (-0.50), W: 38.26 (-1.09), OVAS: 11.28 (+0.45), OFG: 9.41 (+0.19), ALB: 48.91 (+1.30)
BUYINS.NET: BLUE SqueezeTrigger Price is $88.75. There is $267,163,208 That Short Sellers Still Need To Cover.
M2 - Tue Sep 29, 10:07AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Blue Martini Software Inc (NASDAQ:BLUE) in real time and just received an alert that BLUE is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 2969800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $88.75. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BLUE: 94.30 (-0.50)
Weakness Seen in bluebird (BLUE): Stock Tumbles 13.3%
Zacks Equity Research - Zacks Investment Research - Tue Sep 29, 7:38AM CDT
bluebird saw a big move last session as the company's shares fell by over 13% on the day
BLUE: 94.30 (-0.50), ANIK: 32.27 (+0.60)
Alexandria Real Estate Equities, Inc. Announces 10-Year 253,000 RSF Full-Building Build-to-Suit Lease at 60 Binney Street for bluebird bio for Its New Office/Laboratory Headquarters in the Heart of Kendall Square in Cambridge, MA
PR Newswire - Tue Sep 29, 7:30AM CDT
Alexandria Real Estate Equities, Inc. (NYSE: ARE), the largest and leading office REIT uniquely focused on collaborative science and technology campuses in urban innovation clusters, is pleased to announce that bluebird bio, Inc. (Nasdaq: BLUE) executed a 10-year lease for approximately 253,000 rentable square feet (RSF) at 60 Binney Street at the Alexandria Center® at Kendall Square campus. The lease encompasses the entire 60 Binney Street building with the exception of a ground-floor retail suite. With the relocation of its headquarters to 60 Binney Street, bluebird bio, a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, will be expanding its presence in Cambridge to support the company's continued growth. The 60 Binney Street project, which is targeting LEED Gold Certification, is expected to be delivered in late 2016.
BLUE: 94.30 (-0.50), ARE: 88.38 (+0.75)
Global Gene Therapy Market Outlook 2020
M2 - Tue Sep 29, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xn4mxb/global_gene) has announced the addition of the "Global Gene Therapy Market Outlook 2020" report to their offering. According to this new research report Global Gene Therapy Market Outlook 2020, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the gene therapy market, such as phases, geographies, vector types, etc. As indicated by the new estimation carried out in our most recent study, the global gene therapy industry can possibly turn into a multi-million dollar industry by the end of 2020, as new products, particularly those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. The gene therapy market has very few marketed products. The market is majorly in the research phase from which most of its revenue is generated. The report also provides the sales of major marketed gene therapy products and the list of the products in clinical/pre-clinical research along with their clinical phases. The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms, which are aiding them to develop new products. The study highlights the applications for which the investments have been received. Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. The report provides the market analysis of key therapeutic areas along with the forecast till 2020. North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction 4. Industry Overview 5. Clinical Trial Assessment & Pipeline Analysis 6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario 7. Marketed Gene Therapies 8. Global Gene Therapy Market 9. Gene Therapy Market by Application 10. Global Gene Therapy Market Size by Geography 11. Competitive Landscape 12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses) - Advantagene Inc. - Bluebird Bio - Genethon - Human Stem Cells Institute - Oxford BioMedica Plc - Sanofi - Shanghai Sunway Biotech Co. Ltd. - Sibiono GeneTech Co. Ltd. - Spark Therapeutics, LLC - UniQure N.V. - Vical Inc. - ViroMed Co. Ltd. dba VM BioPharma For more information visit http://www.researchandmarkets.com/research/xn...lobal_gene
BLUE: 94.30 (-0.50), VICL: 0.45 (-0.01), ONCE: 44.81 (-5.59)
5 Sell-Ranked Biotechs That Fell More Than 5% Today
A Clark - Zacks Investment Research - Fri Sep 25, 4:53PM CDT
The biotech sector has been struggling as of late, and Friday was an especially tough day for many biotech stocks. Read on for 5 stocks that suffered losses of at least 5% on the day.
BLUE: 94.30 (-0.50), OREX: 2.26 (+0.06), ALDR: 31.14 (-1.43), ACAD: 32.78 (+0.42), ANIP: 45.33 (+1.78)
Why bluebird bio Inc Shares Slumped Again
Brian Feroldi, The Motley Fool - Motley Fool - Fri Sep 25, 2:42PM CDT
What: Shares of bluebird bio , a clinical-stage biotechnology company with a focus on gene therapy, flew south today on heavy trading volume -- its stock was down more than 11% in afternoon trading. So what: For the second time this week...
BLUE: 94.30 (-0.50)
Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet, Global Blood Weighs on Bluebird
at The Street - Fri Sep 25, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 94.30 (-0.50), GBT: 49.11 (+1.07), BMRN: 102.13 (-1.11), GILD: 100.27 (+2.73), ONCE: 44.81 (-5.59), SRPT: 37.97 (-0.03), PTCT: 31.49 (+2.44), IBB: 307.79 (+5.88)
bluebird bio Announces Participation in Leerink Partners Immuno-Oncology Roundtable
Business Wire - Thu Sep 24, 3:05PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in the Leerink Partners Immuno-Oncology Roundtable on Thursday, October 1, 2015, with a fireside chat at 1:30 p.m. ET. The conference is being held at Le Parker Meridien Hotel in New York City.
BLUE: 94.30 (-0.50)
Market Pulse of Healthcare Sector - Concert Pharmaceuticals, Clovis Oncology, bluebird bio, ACADIA Pharmaceuticals and DENTSPLY International
PR Newswire - Thu Sep 24, 7:39AM CDT
ACI Association has initiated research coverage on the following equities: Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), Clovis Oncology, Inc. (NASDAQ: CLVS), bluebird bio, Inc. (NASDAQ: BLUE), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), DENTSPLY International Inc. (NASDAQ: XRAY). On Wednesday, September 23, 2015, NASDAQ ended at 4,752.74 down 0.08%, Dow Jones declined 0.31%, to finish the day at 16,279.89, and the S&P closed at 1,938.76, down 0.20%. Register for your complimentary reports at the links given below.
BLUE: 94.30 (-0.50), ACAD: 32.78 (+0.42), CLVS: 91.75 (+1.36), XRAY: 54.48 (+1.78), CNCE: 20.11 (+1.00)
Did Hillary Clinton Cause bluebird bio to Slump Today?
Brian Feroldi, The Motley Fool - Motley Fool - Mon Sep 21, 1:21PM CDT
What's happening: Shares of bluebird bio , a clinical-stage biotechnology company with a focus on gene therapy, were shot down today on higher than normal volume, falling by more than 12% at one point today before slightly rebounding to a loss of...
BLUE: 94.30 (-0.50)
IPO Stock Watch: Regenxbio Jumps On First Trading Day
at Investor's Business Daily - Thu Sep 17, 3:20PM CDT
Regenxbio (RGNX) popped on the first trading day of its upsized initial public offering, which raised $138.6 million for the drugmaker. Regenxbio priced at 22 and opened at 30.26, up 38%, and remained near there in midday trading. It had previously...
BLUE: 94.30 (-0.50), RGNX: 23.40 (+1.20), ONCE: 44.81 (-5.59), PEN: 41.11 (+1.77), NBRV: 10.27 (unch)
Regenxbio Turns In Strong, Upsized IPO Performance
at Investor's Business Daily - Wed Sep 16, 5:22PM CDT
Regenxbio (RGNX) turned in a strong performance Wednesday, with an upsized initial public offering that raised $138.6 million. The biotech company priced 6.3 million shares, above previous plans to offer 5.6 million shares, at 22 a share. Its initial...
BLUE: 94.30 (-0.50), RGNX: 23.40 (+1.20), ONCE: 44.81 (-5.59), PEN: 41.11 (+1.77), NBRV: 10.27 (unch)
Investor Interest Looks Strong For Regenxbio IPO
at Investor's Business Daily - Wed Sep 16, 4:45PM CDT
Demand for Regenxbio (RGNX) stock is strong heading into the pricing of its initial public offering, scheduled to occur late Wednesday. Research firm IPOboutique.com says channel checks reveal, according to underwriter guidance, that the deal is now...
BLUE: 94.30 (-0.50), ONCE: 44.81 (-5.59)
MPM Capital appoints Mitchell H. Finer PhD, former bluebird bio CSO, as Managing Director.
Business Wire - Tue Sep 15, 1:15PM CDT
MPM Capital announces the appointment of Mitchell H. Finer PhD (Mitch) as Managing Director (MD). Mitch also serves on the Board of Directors of MPM's portfolio company Semma Therapeutics, Inc.
BLUE: 94.30 (-0.50)
Will Kite (KITE) Get Orphan Status Again in EU for KTE-C19?
Arpita Dutt - Zacks Investment Research - Mon Sep 14, 1:56PM CDT
The COMP has adopted a positive opinion regarding the granting of orphan drug status to Kite's (KITE) KTE-C19 for the treatment of PMBCL and MCL.
BLUE: 94.30 (-0.50), GILD: 100.27 (+2.73), KITE: 64.57 (+1.60), AMGN: 148.05 (+6.83)
3 Clinical Trials to Watch As Bluebird Bio Rounds Out 2015
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 14, 1:07AM CDT
bluebird bio is well off its summer highs, but the gene therapy company is still having a solid year, up 44% since January. BLUE data by YCharts The downturn appears to have little to do with what bluebird bio has done -- or not done...
BLUE: 94.30 (-0.50)
